AC Immune SA IPO year
What is the IPO year of AC Immune SA?
The IPO year of AC Immune SA is 2016
What is the definition of IPO year?
Initial public offering is a type of public offering in which shares of a company usually are sold to institutional investors that in turn, sell to the general public, on a securities exchange, for the first time.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO year of companies in the Health Care sector on NASDAQ compared to AC Immune SA
What does AC Immune SA do?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Companies with ipo year similar to AC Immune SA
- The Toronto-Dominion Bank PFD SER 9 3.7% has IPO year of 2015
- Fura Gems has IPO year of 2015
- Hostess Brands has IPO year of 2015
- Nabriva Therapeutics Plc has IPO year of 2015
- REF has IPO year of 2015
- H-Source has IPO year of 2015
- AC Immune SA has IPO year of 2016
- American Pacific Borates has IPO year of 2017
- Razer has IPO year of 2017
- DEAG Deutsche Entertainment Aktiengesellschaft has IPO year of 2017
- Hamilton Beach Brands Co has IPO year of 2017
- Artelo Biosciences has IPO year of 2017
- VARTA AG has IPO year of 2017